Evolution of hepatitis B serological markers in HIV coinfected patients: a case study
ABSTRACT OBJECTIVE To describe the evolution of serological markers among HIV and hepatitis B coinfected patients, with emphasis on evaluating the reactivation or seroreversion of these markers. METHODS The study population consisted of patients met in an AIDS Outpatient Clinic in São Paulo Stat...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Universidade de São Paulo
|
Series: | Revista de Saúde Pública |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102017000100219&lng=en&tlng=en |
id |
doaj-160d4555454e4432a85aefbefceec121 |
---|---|
record_format |
Article |
spelling |
doaj-160d4555454e4432a85aefbefceec1212020-11-24T23:50:56ZengUniversidade de São PauloRevista de Saúde Pública1518-878751010.1590/s1518-8787.2017051006693S0034-89102017000100219Evolution of hepatitis B serological markers in HIV coinfected patients: a case studyAna Luiza de Castro Conde ToscanoMaria Cássia Mendes CorrêaABSTRACT OBJECTIVE To describe the evolution of serological markers among HIV and hepatitis B coinfected patients, with emphasis on evaluating the reactivation or seroreversion of these markers. METHODS The study population consisted of patients met in an AIDS Outpatient Clinic in São Paulo State, Brazil. We included in the analysis all HIV-infected and who underwent at least two positive hepatitis B surface antigen serological testing during clinical follow up, with tests taken six months apart. Patients were tested with commercial kits available for hepatitis B serological markers by microparticle enzyme immunoassay. Clinical variables were collected: age, sex, CD4+ T-cell count, HIV viral load, alanine aminotransferase level, exposure to antiretroviral drugs including lamivudine and/or tenofovir. RESULTS Among 2,242 HIV positive patients, we identified 105 (4.7%) patients with chronic hepatitis B. Follow up time for these patients varied from six months to 20.5 years. All patients underwent antiretroviral therapy during follow-up. Among patients with chronic hepatitis B, 58% were hepatitis B “e” antigen positive at the first assessment. Clearance of hepatitis B surface antigen occurred in 15% (16/105) of patients with chronic hepatitis B, and 50% (8/16) of these patients presented subsequent reactivation or seroreversion of hepatitis B surface antigen. Among hepatitis B “e” antigen positive patients, 57% (35/61) presented clearance of this serologic marker. During clinical follow up, 28.5% (10/35) of those who initially cleared hepatitis B “e” antigen presented seroreversion or reactivation of this marker. CONCLUSIONS Among HIV coinfected patients under antiretroviral therapy, changes of HBV serological markers were frequently observed. These results suggest that frequent monitoring of these serum markers should be recommended.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102017000100219&lng=en&tlng=enHIV infection, Hepatitis B, Chronic, immunologyCoinfectionBiomarkersSeroepidemiologic Studies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ana Luiza de Castro Conde Toscano Maria Cássia Mendes Corrêa |
spellingShingle |
Ana Luiza de Castro Conde Toscano Maria Cássia Mendes Corrêa Evolution of hepatitis B serological markers in HIV coinfected patients: a case study Revista de Saúde Pública HIV infection, Hepatitis B, Chronic, immunology Coinfection Biomarkers Seroepidemiologic Studies |
author_facet |
Ana Luiza de Castro Conde Toscano Maria Cássia Mendes Corrêa |
author_sort |
Ana Luiza de Castro Conde Toscano |
title |
Evolution of hepatitis B serological markers in HIV coinfected patients: a case study |
title_short |
Evolution of hepatitis B serological markers in HIV coinfected patients: a case study |
title_full |
Evolution of hepatitis B serological markers in HIV coinfected patients: a case study |
title_fullStr |
Evolution of hepatitis B serological markers in HIV coinfected patients: a case study |
title_full_unstemmed |
Evolution of hepatitis B serological markers in HIV coinfected patients: a case study |
title_sort |
evolution of hepatitis b serological markers in hiv coinfected patients: a case study |
publisher |
Universidade de São Paulo |
series |
Revista de Saúde Pública |
issn |
1518-8787 |
description |
ABSTRACT OBJECTIVE To describe the evolution of serological markers among HIV and hepatitis B coinfected patients, with emphasis on evaluating the reactivation or seroreversion of these markers. METHODS The study population consisted of patients met in an AIDS Outpatient Clinic in São Paulo State, Brazil. We included in the analysis all HIV-infected and who underwent at least two positive hepatitis B surface antigen serological testing during clinical follow up, with tests taken six months apart. Patients were tested with commercial kits available for hepatitis B serological markers by microparticle enzyme immunoassay. Clinical variables were collected: age, sex, CD4+ T-cell count, HIV viral load, alanine aminotransferase level, exposure to antiretroviral drugs including lamivudine and/or tenofovir. RESULTS Among 2,242 HIV positive patients, we identified 105 (4.7%) patients with chronic hepatitis B. Follow up time for these patients varied from six months to 20.5 years. All patients underwent antiretroviral therapy during follow-up. Among patients with chronic hepatitis B, 58% were hepatitis B “e” antigen positive at the first assessment. Clearance of hepatitis B surface antigen occurred in 15% (16/105) of patients with chronic hepatitis B, and 50% (8/16) of these patients presented subsequent reactivation or seroreversion of hepatitis B surface antigen. Among hepatitis B “e” antigen positive patients, 57% (35/61) presented clearance of this serologic marker. During clinical follow up, 28.5% (10/35) of those who initially cleared hepatitis B “e” antigen presented seroreversion or reactivation of this marker. CONCLUSIONS Among HIV coinfected patients under antiretroviral therapy, changes of HBV serological markers were frequently observed. These results suggest that frequent monitoring of these serum markers should be recommended. |
topic |
HIV infection, Hepatitis B, Chronic, immunology Coinfection Biomarkers Seroepidemiologic Studies |
url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102017000100219&lng=en&tlng=en |
work_keys_str_mv |
AT analuizadecastrocondetoscano evolutionofhepatitisbserologicalmarkersinhivcoinfectedpatientsacasestudy AT mariacassiamendescorrea evolutionofhepatitisbserologicalmarkersinhivcoinfectedpatientsacasestudy |
_version_ |
1725478282065870848 |